ArticlePloS one2014
In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 106 citations in OpenAlex.
- Bixin fromACS omega · 2025Article
- Characterization of a New Hsp110 Inhibitor as a Potential Antifungal.Journal of fungi (Basel, Switzerland) · 2024Article
- Bioprospecting, Synergistic Antifungal and Toxicological Aspects of the Hydroxychalcones and Their Association with Azole Derivates againstPharmaceutics · 2024Article
- Nature-Derived Gelatin-Based Antifungal Nanotherapeutics for combattingEnvironmental science. Nano · 2024Article
- Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review.Antimicrobial agents and chemotherapy · 2023Review
- Candida albicans antibiofilm molecules: analysis based on inhibition and eradication studies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- The Effects of Holothurin and Caspofungin on the Vaginal Cell Inflammation Parameters of theInfection and drug resistance · 2023Article
- Design, Synthesis and Antifungal Evaluation of Novel Pyrylium Salt In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2022Article
- New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets.Pharmaceutics · 2022Article
- Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19.Infectious diseases and therapy · 2022Review
- Article
- Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative AgainstPathogens (Basel, Switzerland) · 2021Article
- Mechanistic Understanding ofFrontiers in microbiology · 2021Review
- Yeast-Host Interactions:Frontiers in pharmacology · 2021Article
- In vivo and in vitro Pathogenesis and Virulence Factors of Candida albicans Strains Isolated from Cutaneous Candidiasis.Iranian biomedical journal · 2020Article
- Candida-Associated Denture Stomatitis and Murine Models: What Is the Importance and Scientific Evidence?Journal of fungi (Basel, Switzerland) · 2020Review
- Predictive Nephrotoxicity Profiling of a Novel Antifungal Small Molecule in Comparison to Amphotericin B and Voriconazole.Frontiers in pharmacology · 2020Article
- Article
- K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-AssociatedFrontiers in microbiology · 2019Article
- Two New 1,3,4-Oxadiazoles With Effective Antifungal Activity AgainstFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistant Candida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity against Candida spp. both in vitro and in vivo. We screened a library of 50,240 small molecules for inhibitors of yeast-to-hypha transition, a major virulence attribute of Candida albicans. This screening identified 20 active compounds. Further examination of the in vitro antifungal and anti-biofilm properties of these compounds, using a range of Candida spp., led to the discovery of SM21, a highly potent antifungal molecule (minimum inhibitory concentration (MIC) 0.2-1.6 µg/ml). In vitro, SM21 was toxic to fungi but not to various human cell lines or bacterial species and was active against Candida isolates that are resistant to existing antifungal agents. Moreover, SM21 was relatively more effective against biofilms of Candida spp. than the current antifungal agents. In vivo, SM21 prevented the death of mice in a systemic candidiasis model and was also more effective than the common antifungal nystatin at reducing the extent of tongue lesions in a mouse model of oral candidiasis. Propidium iodide uptake assay showed that SM21 affected the integrity of the cell membrane. Taken together, our results indicate that SM21 has the potential to be developed as a novel antifungal agent for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.